Read More Pharma Industry News Independent cardiac safety review finds no cardiotoxicity for Moleculin’s annamycin, removing a major anthracycline overhang Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this milestone de-risks the oncology pipeline. bySoujanya RaviJanuary 17, 2026